<p>Patients with multiple myeloma who developed a serious gastrointestinal side effect after treatment with chimeric antigen receptor (CAR) T cell therapy had significantly more CAR T cells persisting in their bloodstream, according to new research from The University of Texas MD Anderson Cancer Center</p>